What You Should Know:
- AccurKardia, Inc., a New York-based medical AI software company delivering clinical-grade ECG interpretation software to cardiac monitoring companies raises $2.7M in seed funding led by Popular Impact Fund alongside other private investors.
- AccurKardia combines proprietary AI and non-AI-based techniques to provide near-real-time ECG analytics in the cloud, on device and at the edge
Clinical-grade, device-agnostic, API-accessible ECG analytics.
AccurKardia solutions include:
- AccurECG: cloud-based web application
- AccurBeat: native iOS app for the Apple Watch ECG
- AccurAPI: API that can be called directly from OEM software
In addition AccurKardia has been selected to join Cohort 3 of Mayo Clinic Platform_Accelerate a program that provides access to Mayo Clinic’s rich, de-identified data sets, validation frameworks, clinical workflow planning, and mentorship. Since March 2023, AccurKardia has been leveraging these assets to accelerate its R&D and clinical validation work.
